IFNG and non-small cell lung carcinoma: In a study of non-small cell lung cancer (NSCLC),22 patients treated with nivolumab or pembrolizumab showed an increase in serum levels of IFNγ, TNFα, as well as many other pro-inflammatory cytokines, which correlated in better responses to anti-PD-1 inhibition and longer survival.